The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
IMG-7289 (bomedemstat), a lysine-specific demethylase-1 (LSD-1) inhibitor, has been granted access to the PRIME (priority medicines) scheme of the European Medicines Agency (EMA) for the treatment of myelofibrosis (MF) based on favorable results from the primary analysis of an ongoing phase II study. LSD-1 is an enzyme involved in the maturation of blood cells, and neoplastic stem and progenitor bone marrow cells, and bomedemstat showed improvements in clinical outcomes including symptom scores, spleen volumes, anemia, and bone marrow fibrosis.1
IMG-7289 (bomedemstat) is currently under investigation in a phase II study (NCT03136185), which is evaluating safety and tolerability, and pharmacokinetics and pharmacodynamic effects in patients with high or intermediate-2 risk primary and secondary MF who are ineligible for, or have become intolerant or resistant to, a Janus kinase inhibitor.2 It is also currently being evaluated for essential thrombocythemia (ET) and polycythemia vera in a number of studies (NCT04262141, NCT04081220, NCT04254978), and has been granted orphan drug and fast track designation for the treatment of MF and ET, and orphan drug designation for acute myeloid leukemia by the U.S. Food and Drug Administration (FDA).1
PRIME is an initiative started by EMA to support the development of medicines that address unmet medical needs. The agency aims to foster an early dialogue with drug developers to accelerate drug development and evaluation.3
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content